Similar articles for PMID: 30034933

Year	Number of Results
2006	1
2008	1
2010	3
2011	1
2012	3
2013	4
2014	5
2015	12
2016	17
2017	9
2018	12
2019	9
2020	2
2021	1
2022	1
2024	0

1

Cancer in a dish: progress using stem cells as a platform for cancer research.

Liu M, Tu J, Gingold JA, Kong CSL, Lee DF. Liu M, et al. Am J Cancer Res. 2018 Jun 1;8(6):944-954. eCollection 2018. Am J Cancer Res. 2018. PMID: 30034933 Free PMC article. Review.

2

Application of induced pluripotent stem cell technology for the investigation of hematological disorders.

Dolatshad H, Tatwavedi D, Ahmed D, Tegethoff JF, Boultwood J, Pellagatti A. Dolatshad H, et al. Adv Biol Regul. 2019 Jan;71:19-33. doi: 10.1016/j.jbior.2018.10.001. Epub 2018 Oct 10. Adv Biol Regul. 2019. PMID: 30341008 Review.

3

Robust Differentiation of mRNA-Reprogrammed Human Induced Pluripotent Stem Cells Toward a Retinal Lineage.

Sridhar A, Ohlemacher SK, Langer KB, Meyer JS. Sridhar A, et al. Stem Cells Transl Med. 2016 Apr;5(4):417-26. doi: 10.5966/sctm.2015-0093. Epub 2016 Mar 1. Stem Cells Transl Med. 2016. PMID: 26933039 Free PMC article.

4

Current status in cancer cell reprogramming and its clinical implications.

Izgi K, Canatan H, Iskender B. Izgi K, et al. J Cancer Res Clin Oncol. 2017 Mar;143(3):371-383. doi: 10.1007/s00432-016-2258-5. Epub 2016 Sep 12. J Cancer Res Clin Oncol. 2017. PMID: 27620745 Review.

5

Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies.

Câmara DA, Mambelli LI, Porcacchia AS, Kerkis I. Câmara DA, et al. J Cancer. 2016 Nov 25;7(15):2296-2303. doi: 10.7150/jca.16629. eCollection 2016. J Cancer. 2016. PMID: 27994667 Free PMC article. Review.

6

Reprogramming cancer cells: overview & current progress.

Lim KL, Teoh HK, Choong PF, Teh HX, Cheong SK, Kamarul T. Lim KL, et al. Expert Opin Biol Ther. 2016 Jul;16(7):941-51. doi: 10.1517/14712598.2016.1174211. Epub 2016 Apr 21. Expert Opin Biol Ther. 2016. PMID: 27070264 Review.

7

Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.

Chen LW, Kuang F, Wei LC, Ding YX, Yung KK, Chan YS. Chen LW, et al. CNS Neurol Disord Drug Targets. 2011 Jun;10(4):449-58. doi: 10.2174/187152711795563994. CNS Neurol Disord Drug Targets. 2011. PMID: 21495962 Review.

8

Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research.

Chao HM, Chern E. Chao HM, et al. J Formos Med Assoc. 2018 Dec;117(12):1046-1057. doi: 10.1016/j.jfma.2018.06.013. Epub 2018 Aug 29. J Formos Med Assoc. 2018. PMID: 30172452 Free article. Review.

9

Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.

Zhu D, Kong CSL, Gingold JA, Zhao R, Lee DF. Zhu D, et al. Adv Exp Med Biol. 2018;1119:169-183. doi: 10.1007/5584_2018_257. Adv Exp Med Biol. 2018. PMID: 30069853 Review.

10

Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.

Liu Y, Deng W. Liu Y, et al. Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28. Brain Res. 2016. PMID: 26423934 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

70 results

Results by year